title: High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study.
abstract: Twenty consecutive patients with poor-risk aggressive lymphoma who at presentation either had elevated serum lactic dehydrogenase level (LDH) and any one of the other poor-prognostic features: bulky mass greater than or equal to 10 cm, advanced stage III or IV, and greater than or equal to 2 extranodal sites, or normal LDH level and all other three features, underwent high-dose chemo/radiotherapy followed by unmanipulated autologous bone marrow transplantation (BMT) during their first complete remission. Eighteen had B-cell lymphoma and 2 had T-cell lymphoma. Eleven patients had high-grade (7 immunoblastic, 3 small noncleaved, non-Burkitt's, and 1 Burkitt's) and 9 had diffuse large cell lymphoma. All patients had achieved a complete remission following conventional chemotherapy. Four patients had also received involved field radiotherapy to areas of bulky disease. The preparative regimen consisted of high-dose etoposide 60 mg/kg and cyclophosphamide 100 mg/kg in combination with fractionated total body irradiation (FTBI) 1,200 cGy (15 patients), or single-dose TBI 750 cGy (2 patients), or carmustine 450 mg/m2 (3 patients). All patients tolerated the treatment well and achieved complete hematologic recovery. Three patients have relapsed at days 79, 196, and 401 after transplantation. Seventeen patients (84%) are alive and relapse-free with a median follow-up of 34 months (range 2 to 54). We conclude that high-dose chemo/radiotherapy followed by autologous BMT can be given as consolidation therapy during first remission in these patients with minimal transplant-related toxicity.
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte 91010.
authors.forename: A
authors.initials: A
authors.lastname: Nademanee
authors.forename: G M
authors.initials: GM
authors.lastname: Schmidt
authors.forename: M R
authors.initials: MR
authors.lastname: O'Donnell
authors.forename: D S
authors.initials: DS
authors.lastname: Snyder
authors.forename: P A
authors.initials: PA
authors.lastname: Parker
authors.forename: A
authors.initials: A
authors.lastname: Stein
authors.forename: E
authors.initials: E
authors.lastname: Smith
authors.forename: J A
authors.initials: JA
authors.lastname: Lipsett
authors.forename: I
authors.initials: I
authors.lastname: Sniecinski
authors.forename: K
authors.initials: K
authors.lastname: Margolin
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D015996:Survival Rate; D014182:Transplantation, Autologous